DexCom, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights - DXCM

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...
Morningstar

ROSEN, NATIONAL TRIAL LAWYERS, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class ...
KELOLAND News

DexCom (DXCM) Blamed Disruptive Sales Force Changes For Its Disappointing Q2 2024 Results And Outlook, Resulting In 40% Stock Drop And Class Action - Hagens Berman

DexCom, Inc. (DXCM) Securities Class Action: DexCom, a leading provider of continuous glucose monitoring systems, is under intense scrutiny from investors and analysts following a disappointing ...
Business Wire

Research and Markets: Dexcom Case Study: Launching a Continuous Glucose Monitor

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/n2btdj/dexcom_case_study) has announced the addition of the "Dexcom Case ...
MobiHealthNews

Dexcom's Kevin Sayer talks new G7 clinical trial data

At the J.P. Morgan Healthcare Conference this week, Dexcom, maker of continuous glucose monitoring systems, made waves after CEO Kevin Sayer announced new clinical trial data from its yet to be ...

Morgan Stanley Upgrades DexCom (DXCM), Cites Undervalued Recovery and G7 Margin Potential

Earlier on November 25, Evercore ISI initiated coverage of DexCom with an In Line rating and $68 price target. While ...
The American Journal of Managed Care

Dexcom's Evidence Builds Case for CGM Dosing Ahead of Key FDA Meeting

The diabetes advocacy community has long sought Medicare coverage for continuous glucose monitoring (CGM) systems, but the technology has been deemed "precautionary." Abstracts presented at last ...
Business Wire

NIH-funded International Diabetes Closed Loop (IDCL) Trial to Combine Technologies from Tandem Diabetes Care, Dexcom and TypeZero

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, Dexcom, Inc.
Business Insider

ROSEN, NATIONAL TRIAL LAWYERS, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCM

New York, New York--(Newsfile Corp. - October 5, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 ...
abc27

ROSEN, LEADING TRIAL ATTORNEYS, Encourages DexCom, Inc. Investors to Secure Counsel Before Important October 21 Deadline in Securities Class Action – DXCM

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class ...
Morningstar

ROSEN, LEADING TRIAL ATTORNEYS, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class ...